Market News (Page 92) - TendieTensor

Market News Page 92 of 167 • 4,159 articles

The Motley Fool • Josh Kohn-Lindquist

Why Progyny Stock Is Soaring Today

11/07/2025 01:02 PM • Progyny reported strong Q3 earnings with 9% sales growth and 23% adjusted growth, maintaining high client retention and demonstrating resilience after losing Amazon as a customer.

PGNY - Exceeded analyst expectations, showed 23% adjusted sales growth, maintained near-100% client retention, and has strong financial position with $300M cash and $200M stock buyback

#fertility #women's health #benefits management #earnings #stock performance

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

GlobeNewswire Inc. • Globe Newswire

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

11/07/2025 01:00 PM • The National Advertising Division will refer BridgeBio Pharma to government agencies after the company failed to participate in an NAD inquiry regarding claims about its Attruby medication's superiority over Pfizer's Vyndamax.

BBIO - Company declined to participate in NAD inquiry and will be referred to government agencies for potential enforcement action

#pharmaceutical #advertising #regulatory #self-regulation #medication

GlobeNewswire Inc. • Randy Gilbert

Table Trac Announces Quarterly Dividend

11/07/2025 12:56 PM • Table Trac Inc. declared a cash dividend of $0.02 per share, payable on December 12, 2025, to shareholders of record as of November 28, 2025.

TBTC - Company announced a cash dividend, indicating financial stability and potential profitability. They also highlighted ongoing market expansion and support contracts in over 300 casinos worldwide.

#dividend #casino #management systems #gaming technology

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

GlobeNewswire Inc. • Hagens Berman

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

11/07/2025 12:54 PM • aTyr Pharma faced a significant securities lawsuit after its Phase 3 drug trial for Efzofitimod failed to meet primary endpoints, causing an 83.2% stock price drop and allegations of misleading investors about the drug's efficacy.

ATYR - Stock price collapsed by 83.2% after failed drug trial, facing securities lawsuit alleging misleading statements about drug efficacy, and potential regulatory challenges

#securities lawsuit #drug trial #clinical trial #pharmaceutical #investor fraud

MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

GlobeNewswire Inc. • Hagens Berman

MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

11/07/2025 12:52 PM • MoonLake Immunotherapeutics faces a securities class action lawsuit after reporting disappointing Phase 3 trial results for its sole drug candidate sonelokimab, causing a 90% stock price drop and allegations of misleading investors about the drug's potential.

MLTX - Stock price dropped 90% after failed Phase 3 trial, facing lawsuit alleging intentional investor deception about drug candidate's efficacy and potential

#securities lawsuit #biotechnology #clinical trials #investor fraud

SalMar - Release of employee restricted share units in SalMar ASA (

GlobeNewswire Inc. • Håkon Husby

SalMar - Release of employee restricted share units in SalMar ASA ("the Company")

11/07/2025 12:50 PM • Primary insiders at SalMar settled 155,799 restricted share units (RSUs) on November 7th, 2025, with several executives receiving and subsequently selling shares to cover tax liabilities at a market price of NOK 573.004 per share.

SALRY - The article describes a routine RSU settlement process with no significant positive or negative financial implications, representing standard corporate governance and compensation practices

#RSU #share settlement #insider trading #tax liability

AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday?

Benzinga • Piero Cingari

AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday?

11/07/2025 12:45 PM • AI and technology stocks experienced significant selloff on Friday, with the Nasdaq 100 dropping nearly 5% for the week amid economic uncertainty and declining consumer sentiment.

NVDA - Stock fell 4%, with weekly losses exceeding 10% during the AI stock selloff

#AI stocks #technology #market selloff #consumer sentiment #economic indicators

Navitas $100M Capital Raise Extends Runway Yet Highlights Balance-Sheet Risk

Investing.com • Timothy Fries

Navitas $100M Capital Raise Extends Runway Yet Highlights Balance-Sheet Risk

11/07/2025 12:45 PM • Navitas Semiconductor raised $100 million through a private placement offering, selling 14.8 million shares at $6.75 per share, which caused its stock to decline 13.19%. The capital raise aims to support the company's strategic transformation into 'Navitas 2.0', focusing on high-power markets like AI data centers and energy infrastructure.

NVTS - Stock declined 13.19% due to share dilution, discounted share price, and ongoing financial losses (negative Q3 earnings of -$10.18 million and trailing twelve-month net loss of $125 million)

#capital raise #semiconductor #GaN #SiC #AI #power infrastructure

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment

Benzinga • Vandana Singh

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment

11/07/2025 12:33 PM • Eli Lilly reported promising Phase 2 trial results for eloralintide, an investigational obesity drug that demonstrated weight loss up to 20% in obese adults, with potential improvements in cardiometabolic risk factors.

NVDA - Mentioned as part of the AI chip ecosystem, but no specific analysis provided in the article
LLY - Successful Phase 2 trial showing significant weight loss and potential for new obesity treatment, with analysts viewing the drug as an emerging cornerstone in obesity management

#obesity #weight loss #clinical trial #drug development #amylin receptor agonist

Infant Formula Market to Worth USD 207.19 Billion by 2034, Driven by Urbanization and Growing Demand for Convenient Nutrition Solutions

GlobeNewswire Inc. • Towards Healthcare

Infant Formula Market to Worth USD 207.19 Billion by 2034, Driven by Urbanization and Growing Demand for Convenient Nutrition Solutions

11/07/2025 11:00 AM • The global infant formula market is projected to grow from USD 90.27 billion in 2025 to USD 207.19 billion by 2034, driven by urbanization, working mothers, and increased nutritional awareness. Asia-Pacific leads the market, with North America expected to see significant growth.

ABT - Mentioned as a key market player in a growing infant formula market with strong projected expansion

#infant formula #nutrition #market growth #urbanization #working mothers

ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

GlobeNewswire Inc. • Adarx Pharmaceuticals

ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

11/07/2025 11:00 AM • ADARx Pharmaceuticals reported successful Phase 1 clinical trial results for ADX-038, an investigational siRNA therapy targeting complement factor B. A single subcutaneous dose demonstrated near-complete alternative pathway suppression for 6 months, with potential applications in renal, hematologic, and ocular diseases.

ABBV - Mentioned as a collaboration partner for siRNA therapeutics development, with no specific performance details provided

#siRNA #complement factor B #Phase 1 clinical trial #RNA therapeutics #alternative pathway

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

11/07/2025 11:00 AM • The Schall Law Firm is pursuing a securities fraud lawsuit against MoonLake Immunotherapeutics for allegedly misleading investors about its drug candidate sonelokimab, which resulted in a significant stock price drop after disappointing Phase 3 trial results.

MLTX - Company allegedly made false statements about drug candidate, misled investors, experienced 90% stock value loss after Phase 3 trial results, and is now facing a securities fraud lawsuit

#securities fraud #lawsuit #class action #drug trial #stock market

New Enterprise Stone & Lime Co., Inc. Enters Into Amendment No. 8 of the Revolving Credit Agreement

GlobeNewswire Inc. • Eric Thiele

New Enterprise Stone & Lime Co., Inc. Enters Into Amendment No. 8 of the Revolving Credit Agreement

11/07/2025 11:00 AM • New Enterprise Stone & Lime Co., Inc. entered into Amendment No. 8 of its Revolving Credit Agreement with PNC Bank, extending the maturity date to 2030 and increasing the credit limit from $105 million to $150 million.

PNC - Bank continues existing lending relationship with no significant changes in risk profile

#credit agreement #revolving credit #financing #banking

Security National Financial Corporation Announces Q3 Earnings Call

GlobeNewswire Inc. • Security National Financial Corporation

Security National Financial Corporation Announces Q3 Earnings Call

11/07/2025 11:00 AM • Security National Financial Corporation will hold a 30-minute earnings call on November 14, 2025, at 1 PM MST to discuss its third quarter financial results and provide updates on its three business segments.

SNFCA - The article is a standard earnings call announcement with no explicit positive or negative financial indicators, presenting routine corporate communication about upcoming financial reporting

#earnings call #Q3 results #financial reporting #investor relations

Flutter Entertainment Announce Management Participation in Upcoming Event

GlobeNewswire Inc. • Flutter Entertainment

Flutter Entertainment Announce Management Participation in Upcoming Event

11/07/2025 11:00 AM • Flutter Entertainment's CEO and CFO will participate in a Morgan Stanley fireside chat on November 19, 2025, providing investors an opportunity to hear about the company's current performance and strategy.

FLUT - The company is proactively engaging with investors, showcasing transparency and confidence by hosting a public fireside chat with senior leadership

#investor relations #fireside chat #sports betting #iGaming

Heart of Hong Kong is Transformed into Winter Wonderland with Eight Iconic Buildings used as Canvas for New Immersive Lights Show

GlobeNewswire Inc. • Globe Newswire

Heart of Hong Kong is Transformed into Winter Wonderland with Eight Iconic Buildings used as Canvas for New Immersive Lights Show

11/07/2025 10:56 AM • Hong Kong is transforming Central into a winter wonderland for the 2025 WinterFest, featuring an immersive light show projecting festive scenes on eight iconic buildings, a 20-meter Christmas tree, and a Christmas market from November 14, 2025 to January 4, 2026.

HNGKY - Collaborating with Hong Kong Tourism Board to create Winter Wonderland event, enhancing city's festive atmosphere

#WinterFest #Christmas #Hong Kong #light show #tourism #winter destination

CORRECTION -- TIAN RUIXIANG Holdings Ltd. Enters Into Agreement to Acquire REN Talents Inc.

Benzinga • Globe Newswire

CORRECTION -- TIAN RUIXIANG Holdings Ltd. Enters Into Agreement to Acquire REN Talents Inc.

11/07/2025 10:48 AM • TIAN RUIXIANG Holdings Ltd. announced its acquisition of REN Talents Inc., a creative brand agency with offices in New York and Paris, for 3,211,010 Class A ordinary shares at $2.18 per share. The acquisition aims to expand TRX's global presence and diversify its business beyond insurance.

COFpI - Announced $16 billion buyback program (11.2% of market cap), increased buyback spending pace, and delivered 27% stock return in 2025
TIRX - Company is strategically expanding into international markets, diversifying its business model, and gaining access to new consumer touchpoints

#acquisition #brand agency #globalization #insurance #creative marketing

Velocity Financial VEL Q3 2025 Earnings Transcript

The Motley Fool • Motley Fool Transcribing

Velocity Financial VEL Q3 2025 Earnings Transcript

11/07/2025 10:32 AM • Velocity Financial reported record pretax earnings of 66.5% in Q3 2025, with loan production reaching $739 million and net income up 60% year-over-year. The company closed its first single counterparty securitization and maintained strong credit discipline despite temporary real estate owned asset revaluations.

BEPH - Same positive attributes as Brookfield Renewable, with complementary business structure and growth prospects
VEL - Strong financial performance with record pretax earnings, increased loan production, successful securitization, stable portfolio metrics, and positive management outlook

#earnings #loan production #securitization #financial performance #real estate

Solventum (SOLV) Q3 2025 Earnings Call Transcript

The Motley Fool • Motley Fool Transcribing

Solventum (SOLV) Q3 2025 Earnings Call Transcript

11/07/2025 10:27 AM • Solventum reported strong Q3 2025 financial performance, with solid growth in MedSurg, Dental Solutions, and Health Information Systems segments. The company is advancing toward long-range revenue and earnings objectives faster than anticipated, with a focus on strategic acquisitions and operational efficiency.

BEPI - Same positive attributes as Brookfield Renewable, with complementary business structure and growth prospects
SOLV - Reported 1.1% organic growth in MedSurg, successful ERP implementation, strong performance in dental and health information systems, and progressing faster than expected towards long-range revenue targets

#earnings #medical technology #financial performance #mergers and acquisitions #operational efficiency

Cleared Out: CyberArk Software Stock Sacrificed for New Opportunities

The Motley Fool • Jake Lerch

Cleared Out: CyberArk Software Stock Sacrificed for New Opportunities

11/07/2025 10:22 AM • Herald Investment Management Ltd sold its entire $17.2 million stake in CyberArk Software, completely exiting the position despite the company's strong recent stock performance.

BEPJ - Same positive attributes as Brookfield Renewable, with complementary business structure and growth prospects
CYBR - Despite strong historical stock performance (250% return over three years), the complete exit by Herald Investment Management suggests potential strategic repositioning or profit-taking, warranting a neutral sentiment

#cybersecurity #institutional investment #stock sale #privileged access management

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The Motley Fool • Rick Munarriz

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

11/07/2025 10:15 AM • Cathie Wood of Ark Invest purchased shares in Archer Aviation, DoorDash, and Tempus AI during a volatile market day, showing her strategy of investing in emerging technologies despite current market fluctuations.

BEPpA - Same positive attributes as Brookfield Renewable, with complementary business structure and growth prospects
ACHR - Pre-revenue company with potential in electric vertical takeoff and landing aircraft, partnering for Olympic Games, but currently experiencing stock price volatility

#Cathie Wood #growth stocks #emerging technologies #market volatility #investment strategy

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Benzinga • Vandana Singh

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

11/07/2025 10:10 AM • Gilead Sciences reported mixed results from a Phase 3 breast cancer study of Trodelvy, which did not meet its primary endpoint of progression-free survival but showed an early trend in overall survival. The drug's safety profile remained consistent with previous studies.

GILD - Study results were mixed - missed primary endpoint but showed potential early survival trend, indicating neither a clear success nor complete failure

#breast cancer #clinical trial #pharmaceutical research #oncology

Digital Tattoos Market Valued at USD 4.57 Billion in 2024, Projected to Surpass USD 8.50 Billion by 2032 | Research by SNS Insider

GlobeNewswire Inc. • Sns Insider

Digital Tattoos Market Valued at USD 4.57 Billion in 2024, Projected to Surpass USD 8.50 Billion by 2032 | Research by SNS Insider

11/07/2025 10:00 AM • The digital tattoos market is projected to grow from USD 4.57 billion in 2024 to USD 8.50 billion by 2032, driven by advancements in bio-integrated sensors, flexible electronics, and IoT connectivity for health monitoring applications.

GOOG - Partnered with VivaLNK to enhance health monitoring capabilities through digital tattoo technology with a 5-7 year partnership

#digital tattoos #wearable technology #healthcare #IoT #bio-integrated sensors

E-Pharmacy Market Set to Quadruple, Reaching USD 435.82 Billion by 2034, Reports Towards Healthcare

GlobeNewswire Inc. • Towards Healthcare

E-Pharmacy Market Set to Quadruple, Reaching USD 435.82 Billion by 2034, Reports Towards Healthcare

11/07/2025 10:00 AM • The global E-pharmacy market is expected to grow from USD 96.94 billion in 2024 to USD 435.82 billion by 2034, with a 16.44% CAGR. North America currently leads the market, while Asia Pacific is anticipated to be the fastest-growing region, driven by technological innovations and digital health initiatives.

MSFT - Cited as an example of using consistent revenue streams to invest in emerging technologies, with strong operating margins
CVS - Mentioned as a key player in the growing E-pharmacy market with strong market presence

#E-pharmacy #Digital health #Telemedicine #Online pharmacy #Healthcare technology

Packaging Waste Management Market Size, Trends, Segments, Share and Companies 2025-35

GlobeNewswire Inc. • Towards Packaging

Packaging Waste Management Market Size, Trends, Segments, Share and Companies 2025-35

11/07/2025 10:00 AM • The global packaging waste management market is projected to grow from $39.78 billion in 2025 to $54.21 billion by 2034, with a 3.5% CAGR. Asia Pacific leads the market, driven by industrialization and sustainability initiatives, while North America shows rapid growth through advanced recycling technologies and environmental regulations.

META - Mentioned as an example of using stable revenue to fund future technology development, with high operating margins
WM - Provides integrated packaging waste management services with significant investments in advanced recycling infrastructure

#packaging waste management #recycling #sustainability #circular economy #waste management